<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02244294</url>
  </required_header>
  <id_info>
    <org_study_id>527.26</org_study_id>
    <nct_id>NCT02244294</nct_id>
  </id_info>
  <brief_title>FLOMAX® Versus Placebo, in Male Patients With Acute Urinary Retention Related to Benign Prostatic Hyperplasia (BPH)</brief_title>
  <official_title>A Two Phase, Double-blinded, Randomized, Parallel Group Design, Multicenter Study of FLOMAX® Capsules, 0.4 mg Versus Placebo, in Male Patients With Acute Urinary Retention Related to Benign Prostatic Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To establish whether the administration of FLOMAX® improves the outcome of a trial without
      catheter (TWOC) after an episode of acute urinary retention and to determine whether
      spontaneous voiding is maintained over the course of six months of active treatment
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2001</start_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Successful spontaneous voiding after urethral catheter removal</measure>
    <time_frame>Up to 96 hours after start of treatment</time_frame>
    <description>For Phase I of the trial</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maintenance of successful spontaneous voiding</measure>
    <time_frame>Up to 6 months after start of treatment</time_frame>
    <description>For Phase II of the trial</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in voided urine volume</measure>
    <time_frame>Up to 6 months after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of post-void residual urine volume</measure>
    <time_frame>Up to 6 months after start of treatment</time_frame>
    <description>by ultrasound or bladder scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence of AUR</measure>
    <time_frame>Up to 6 months after start of treatment</time_frame>
    <description>For phase II of the trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes from baseline in vital signs</measure>
    <time_frame>Pre-dose, up to 6 months after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">176</enrollment>
  <condition>Prostate Hyperplasia</condition>
  <arm_group>
    <arm_group_label>FLOMAX®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FLOMAX® capsules</intervention_name>
    <arm_group_label>FLOMAX®</arm_group_label>
    <other_name>Tamsulosin hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo capsules</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Phase I

          -  Adult men, 45 years of age or older, diagnosed with acute urinary retention due to BPH

          -  Patients who have never taken alpha-blockers or discontinued taking alpha-blockers 72
             hours or more prior to entrance into this study

          -  Patients that have been treated with an indwelling urethral catheter as treatment for
             acute urinary retention (AUR) due to BPH

          -  Patients must be judged by the investigator to be reliable and willing to comply with
             all tests and examinations stipulated in the protocol

          -  All patients must be willing to give meaningful, written, informed consent prior to
             participation in the trial, in accordance with regulatory requirements. Patients must
             also have sufficient understanding to communicate effectively with the investigator

        Phase II - Patients who voided spontaneously, at least 100 mL and a post-void residual
        volume of ≤ 300 mL, at Visit 2

        Exclusion Criteria:

        Phase I

          -  Patients diagnosed with a symptomatic/active urinary tract infection (UTI) or an
             abnormal urine culture at baseline or 2 or more UTIs within the last six months. An
             abnormal urine culture was defined as:

               -  A bacterial colony count of greater than or equal to 100,000 CFU/mL or

               -  A bacterial colony count of greater than or equal to 100 CFU/mL of a known
                  urinary pathogen in a symptomatic patient

          -  Patients that have a distended bladder volume greater than 1.5 liters (1500 ml) of
             retention as measured by initial catheter urine volume

          -  Patients with history of sexually transmitted disease within last two years

          -  Patients with active genital herpes disease whose urinary function was impacted due to
             the disease

          -  Patients who have a history of mechanical outlet obstruction excluding BPH (i.e.,
             bladder neck contracture or stricture, bladder tumor, or bladder calculi)

          -  Patients with urethral stricture disease

          -  Patients with a history of bladder, prostate, or urethral surgery in the last three
             months

          -  Patients presenting with AUR who were not been seen within 5 days of urethral catheter
             placement

          -  Patients presenting with any of the following: active urinary stone disease, previous
             pelvic radiotherapy, perirectal inflammatory disorders or inflammatory bowel disease

          -  Participation in another drug study within 30 days of Visit 1

          -  Clinically relevant conditions which may interfere with the patient's ability to
             participate in the study including, but not limited to, the following: neurologic,
             gastrointestinal, cardiovascular, hepatic, renal, psychiatric, hematologic or
             respiratory disease and clinically relevant laboratory abnormalities not mentioned
             above (e.g., hematuria) based upon the clinical judgment of the investigator

          -  Patients receiving cimetidine, ranitidine or warfarin within two weeks of study start
             date and who would potentially use such medications during the course of the trial

          -  Patients currently treated with finasteride (PROSCAR®) and who would not discontinue
             its use upon entrance into the study

          -  Patients with known hypersensitivity to FLOMAX® (tamsulosin hydrochloride) or other
             alpha-blockers

          -  Patients with a history of myocardial infarction within six months of baseline

          -  Patients with uncontrolled hypertension (systolic &gt; 160 mmHg, diastolic &gt; 100 mmHg)
             and patients with severe hypotension (systolic &lt; 90 mmHg)

          -  Patients who have been using the following drugs, 72 hours prior to study start date,
             or who are unable to discontinue these drugs over the course of the study:

               -  Alpha-adrenergic medication

               -  Drugs with systemic anticholinergic activity including antihistamines. The
                  following antihistamines are allowed: ALLEGRA®, CLARITIN® or ZYRTEX®

               -  Antispasmodics or muscle relaxants

               -  Parasympathomimetics, cholinomimetics or similar drug

          -  Patients that have poorly controlled diabetes mellitus who suffer from peripheral
             neuropathy or diabetic cystopathy

          -  Patients who suffer from neurological diseases affecting the bladder (i.e., multiple
             sclerosis, Parkinson's disease, stroke, and any bladder trauma that may be an
             exclusion criterion in the opinion of the investigator

          -  Patients with a neurological impairment or psychiatric disorder that prevents their
             comprehension of the informed consent and/or the ability to comply with the protocol

          -  Patients with a urine volume at the initial catheterization less than 300 mL

          -  Patients with a diagnosis of active cancer, except basal cell carcinoma, within 5
             years or less

          -  Patients who had a transurethral resection of the prostate (TURP) within 5 years or
             less of study enrollment and irreversible urethral damage due to the procedure

        Phase II

        - Patients with clinically, significant abnormal lab results including any baseline
        laboratory serum test with the following values:

          -  Hemoglobin &lt; 11.0 g/dL

          -  Leukocytes &lt; 3,000 per mm3

          -  Liver enzymes [aspartate aminotransferase (SGOT), alanine transaminase (SGPT) and
             alkaline phosphatase]: more than two times the upper limit of normal at baseline

          -  Serum creatinine more than two times the upper limit of normal at Visit 1

          -  Patients with clot retention, persistent gross hematuria (Visit 3 only), prostatitis,
             a symptomatic/active urinary tract infection (UTI) or an abnormal baseline urine
             culture

          -  An abnormal urine culture was defined as:

          -  A bacterial colony count of greater than or equal to 100,000 colony forming units
             (CFU)/mL or

          -  A bacterial colony count of greater than or equal to 100 CFU/mL of a kown urinary
             pathogen in a symptomatic patient
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2014</study_first_submitted>
  <study_first_submitted_qc>September 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2014</study_first_posted>
  <last_update_submitted>September 18, 2014</last_update_submitted>
  <last_update_submitted_qc>September 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Urinary Retention</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

